Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026

Other non-cash items growth accelerates

Q2 FY2026 other non-cash items of $44.44M rose 197.7% year over year, ahead of the +128.9% change in trailing-twelve-month other non-cash items. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +26.2% a year.

Context

  • Other non-cash items amounted to 7.2% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +197.7% holds above the trailing-twelve-month pace of +128.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$44.44M+10.6% QoQ
Last fiscal yearDec 2025
$216.93M+98.9% YoY
LTMJun 2026
$232.33M+128.9% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+197.7%——
1 year+98.9%——
3-year CAGR+26.2%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
216.93M USD
Year-over-year change
+98.9%
4-year CAGR
+13.4%

Other Non-Cash Items vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +128.9% is the 4th highest of 11, against a peer median of -0.5%.
  • Other non-cash items amounts to 7.5% of revenue for AMRX, versus a peer median of 4.8%.
AMRX Competitors
Other Non-Cash Items for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTRSViatris Inc.LTM Jun 2026$2.7B USD-35.5%—18.3%
PRGOPerrigo Company plcLTM Jun 2026$2.11B USD+1526.4%+123.6%50.9%
BHCBausch Health Companies Inc.LTM Jun 2026$1.68B USD+2337.1%-90.7%15.5%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹1.66B INR-90.3%—0.5%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$1.63B USD+4.4%-22.3%9.4%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$232.33M USD+128.9%+26.2%7.5%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$51M USD+0.0%—3.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$37.96M USD+271.1%—5.3%
EBSEmergent BioSolutions Inc.LTM Mar 2026$28.7M USD-1.0%+17.8%4.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$12.05M USD-153.3%—1.3%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$1.24M USD-49.5%-71.7%3.0%
Peer median (excluding AMRX) —-0.5%-22.3%4.8%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income10.62M(254.79M)(48.72M)(73.88M)72.06M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
Deferred Income Tax00000
Stock-Based Compensation031.85M26.82M27.77M31.95M
Change in Working Capital(133.59M)(59.95M)(47.19M)(4.07M)(204.52M)
Accounts Receivables(16.31M)(79.07M)125.8M(162.16M)(120.57M)
Inventory(49.02M)(102.4M)(126.18M)(130.53M)(87.03M)
Accounts Payables(43.93M)109.57M(94.45M)235.14M21.32M
Other Working Capital(24.34M)11.95M47.64M53.48M(18.23M)
Other Non-Cash Items131.38M107.81M185.26M109.08M216.93M
Operating Cash Flow241.82M65.1M345.58M295.1M339.99M
Capital Expenditures(47.73M)(90.6M)(69.19M)(74.99M)(70.06M)
Acquisitions (Net)(141.54M)(84.71M)011.99M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.21M)(40.8M)(22.39M)(14.65M)(42.2M)
Investing Cash Flow(194.18M)(174.31M)(69.19M)(63M)(112.26M)
Debt Repayment(79.18M)(38.27M)22.65M(185.12M)26.27M
Common Stock Issued853K0001.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(59.8M)(68.35M)(235.23M)(26.67M)(59.76M)
Financing Cash Flow(138.12M)(106.62M)(212.57M)(211.79M)(31.53M)
Effect of Forex Changes102K(5.68M)65K(999K)(1.68M)
Net Change in Cash(90.38M)(221.51M)63.88M19.31M194.52M
Free Cash Flow194.09M(25.5M)276.39M220.11M269.93M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.